Hep-V Vax

Developed for: hepatitis B virus infection · liver and intrahepatic bile duct neoplasm
Investigated by: Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Merck Institute for Therapeutic Research · Qidong Liver Cancer Institute · University of Oxford

Trials 1

today NCT00222664 · Ph 4

1983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 4	NCT00222664	Sep 1983 → Dec 2004	hepatitis B virus infection, liver and intrahepatic bile duct neoplasm	University of Oxford	Completed	No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Hep-V Vax	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00222664 ↗